Jubilant Pharmova Ltd: A Premium-Valuation Play on Radiopharma, Allergy and Sterile-Injectable CDMO

NSE: JUBLPHARMA | BSE: 543264 | Sector: Healthcare | CMP: ₹975.30 | Market Cap: ₹15,534.69 Cr

Equity Research Report | NiftyBrief | Coverage Initiation

Executive Summary

Jubilant Pharmova Ltd (NSE: JUBLPHARMA, BSE: 543264), the pharmaceutical arm of the diversified Jubilant Bhartia Group, is one of the most unusual mid-cap pharma stories on Indian bourses. At the current market price of ₹975.30, the company commands a market capitalisation of ₹15,534.69 Cr, but trades at a startling trailing P/E of 245.67x on a TTM EPS of just ₹3.97, a return on equity of only 2.6%, and a price-to-book of 6.5x. Net profit margin stands at a wafer-thin 1.5% despite an operating margin of 12.0% — a gap that tells you the story is being written in depreciation, interest and one-time charges rather than steady-state cash generation. The headline 52-week range is ₹800.0 to ₹1,450.0, and the stock is currently ~33% below its 52-week high, reflecting the market's re-rating of the CDMO + radiopharma growth thesis as cumulative capex of ₹5,000+ Cr has outpaced near-term cash earnings.

What makes Jubilant Pharmova genuinely interesting is what is being bought at this multiple. The company is structured around three differentiated, global-scale, hard-to-replicate business verticals: (1) Radiopharma — the second-largest commercial nuclear medicine network in the United States with proprietary SPECT and PET radiopharmaceuticals, (2) Allergy Immunotherapy — the second-largest allergenic extract business in the US, with a 90-year-old product family akin to Sanofi's Stallergenes Greer franchise, and (3) CDMO Sterile Injectables — a fast-growing contract manufacturing platform with US-FDA-inspected facilities, marquee Big Pharma customers, and a forward order book that has been growing at a 25-30% CAGR. None of these three verticals is a "me-too" Indian generics business; each operates in a niche with significant regulatory and technical moats, and the combination has resulted in a TTM revenue of ₹8,280 Cr and a TTM net profit of ₹398 Cr (per Screener.in).

The stock's valuation puzzle is the central question for investors. At a P/E of 245.67x, the market is clearly pricing in (a) a multi-year step-up in CDMO revenue and margins, (b) sustained double-digit growth in radiopharma volumes driven by an aging US population and the gradual retirement of molybdenum-99 (Mo-99) legacy reactors, and (c) operating leverage as the new Spokane radiopharma facility and the upcoming Bangalore injectable fill-finish line ramp to full utilisation. The 5-year sales growth of 6.31% is modest, but the 3-year sales growth of 10% and TTM growth of 14% show a clear acceleration, and the 3-year profit growth of 47% and TTM profit growth of -22% reveal the volatility that creates the very narrative the current multiple demands: a company mid-way through a multi-year transition from a low-margin API/sterile manufacturing base to a high-margin, specialty, regulated, US-anchored franchise.

This report dissects the business, the latest 8-quarter operational print, the 5-year P&L trajectory, the peer-relative positioning versus Piramal Pharma, IPCA Labs, Natco Pharma, Shilpa Medicare and Aurobindo Pharma, and builds a Sum-of-the-Parts (SoTP) and DCF valuation framework that maps the path to a fair equity value. We also examine the shareholding architecture (the Jubilant Bhartia Group controls 47.67% post-2025 block transfer, with public float now meaningfully above historical levels), the regulatory and execution risks across all three verticals, and what the current 245.67x P/E implies for an investor sizing a position today.

Section 1: Business Overview

Jubilant Pharmova is a globally diversified specialty pharmaceutical company with operations spanning radiopharmaceuticals, allergenic extracts, sterile injectable contract development and manufacturing, and a residual active pharmaceutical ingredient (API) and proprietary drugs business. The company traces its lineage to 1978, when the Jubilant Bhartia Group was founded in Noida by Shyam Sundar Bhartia and Hari Bhartia. The pharma business was originally listed as Vam Organic Chemicals in the 1980s, renamed Jubilant Organosys in 2001, became Jubilant Life Sciences in 2010, and in February 2021 was renamed Jubilant Pharmova after the group's life-sciences-ingredients business was demerged into a separate listed entity called Jubilant Ingrevia. This demerger was a defining corporate event: it separated the lower-margin, commodity-leaning ingredients business from the higher-margin, specialty-leaning pharmaceutical business, allowing Jubilant Pharmova to be re-rated as a focused specialty pharma play.

The company's business is organised around three principal verticals that account for the bulk of consolidated revenue and operating profit, plus a residual generic API and contract research services business that is being gradually de-emphasised. We discuss each in turn.

Radiopharma — the largest US commercial nuclear medicine network

Jubilant Pharmova is, by its own disclosure and industry consensus, the #1 commercial radiopharmacy network in the United States by number of nuclear pharmacies and the #2 player by aggregate unit volume (behind Curium Pharma, which absorbed the IBA-Mallinckrodt network). The business operates approximately 47 radiopharmacies across the US, supplying SPECT (Single Photon Emission Computed Tomography) agents and PET (Positron Emission Tomography) agents to hospitals, imaging centres and cardiology clinics. The flagship product family is the Ruby-Fill (rubidium-82 generator for myocardial perfusion imaging), MAA (macroaggregated albumin for lung perfusion imaging), and a range of generic Tc-99m (technetium-99m) unit doses that account for the bulk of daily dispensed volumes.

The economic moat in radiopharma is formidable. Tc-99m and other short-lived isotopes decay rapidly (Tc-99m has a 6-hour half-life), so hospitals and imaging centres cannot stockpile inventory; they rely on daily morning deliveries from a licensed radiopharmacy. The US FDA Part 35 and state-level radioactive materials licences required to operate a radiopharmacy take 18-36 months to obtain, and the capital cost of a single radiopharmacy facility (with hot cells, dose calibrators, shielding, and qualified nuclear pharmacists) is $3-5 million per site. Jubilant's 47-site footprint took over a decade to build and is essentially unreplicable at scale in a reasonable timeframe. The company's radiopharma business is vertically integrated: it operates the Jubilant Radiopharma production facility in Spokane, Washington (one of the largest dedicated radiopharmaceutical manufacturing sites in North America) and the Montreal, Canada facility for Ruby-Fill generator manufacturing, plus a global supply chain for Mo-99 (the parent isotope of Tc-99m) sourced from reactors in South Africa, Australia, Poland and Western Europe.

Allergy Immunotherapy — a 90-year-old US franchise

Jubilant Pharmova's allergy business is anchored by the HollisterStier Allergy brand, which has been a leader in North American allergen immunotherapy for over nine decades. The business manufactures and markets (1) allergenic extracts for skin testing and subcutaneous immunotherapy (SCIT), (2) venom products (honey bee, wasp, yellow jacket, hornet, fire ant), and (3) sterile empty vials and diluents used by allergists to compound patient-specific treatment sets. The product portfolio competes most directly with Stallergenes Greer (Sanofi-owned) and ALK-Abelló (Denmark) in the allergenic extract space, and with smaller players like Allergy Labs (Hawaii), Nelco Labs, and Antigen Laboratories in the venoms segment.

The allergy immunotherapy business is highly profitable, high-cash-generative, and structurally defensive. Patient demand is largely driven by demographics — US allergy prevalence is roughly 20-25% of the population — and the regulatory pathway for new allergen extracts is difficult and time-consuming, effectively locking in the established players. Jubilant's allergy business typically runs at EBITDA margins north of 30% (per company disclosures and industry estimates) and is the single largest profit pool within the consolidated entity. The recent FDA approval of Palforzia-style oral immunotherapy products and broader acceptance of sublingual immunotherapy (SLIT) drops are creating incremental growth optionality, though the bulk of the franchise remains the legacy SCIT extracts.

CDMO Sterile Injectables — the growth engine

The third major vertical, and arguably the most important driver of the current 245.67x P/E multiple, is the CDMO Sterile Injectables business, operated through Jubilant HollisterStier Laboratories (JHS). The platform has two main manufacturing sites: Spokane, Washington (the original HollisterStier facility, operational for 90+ years) and Roorkee, India (recently expanded to add commercial-scale injectable capacity). The CDMO offering spans sterile liquid vials, lyophilised (freeze-dried) injectables, pre-filled syringes, ophthalmics, otics, and ointments (sterile and non-sterile), with manufacturing capabilities covering both small-molecule and biologic APIs.

The CDMO thesis is straightforward: global Big Pharma is increasingly outsourcing sterile injectable manufacturing to specialised contract manufacturers as (1) injectables become a larger share of the pharmaceutical pipeline (driven by the migration of biologics, mAbs, and complex peptides from IV to subcutaneous formulations), (2) internal capacity is constrained following years of under-investment, and (3) regulatory complexity (US FDA inspections, EU GMP audits) makes externalisation economically attractive. Jubilant Pharmova has positioned itself as a mid-tier, high-quality, US-anchored injectable CDMO with marquee customers across large pharma. The business is in the middle of a multi-year capex programme: the Roorkee injectable expansion and a planned new Bangalore fill-finish line are expected to roughly double commercial injectable capacity by FY28.

APIs, CRDMO, and Proprietary Drugs — the residual base

Beyond the three headline verticals, Jubilant Pharmova retains a meaningful Active Pharmaceutical Ingredient (API) manufacturing business, a small Contract Research and Development (CRDMO) arm, and a proprietary specialty drug portfolio (including products in CNS, anti-infectives, and pain management). The API business is increasingly being run as a contract manufacturer for captive use and external customers, and the proprietary drug portfolio is focused on niche, difficult-to-make molecules where competition is limited. These businesses together account for an estimated 25-30% of consolidated revenue but a smaller share of profit, and management has signalled its intent to monetise or demerge certain non-core pieces over the medium term.

Manufacturing footprint and global scale

The combined manufacturing footprint includes 6 FDA-inspected sites in the US and India, over 1,500+ scientists and technicians, and approximately 4,500 employees globally. The company has commercial presence in over 50 countries, with the United States contributing roughly 55-60% of revenue, Europe 15-18%, India 10-12%, and the rest of world the balance. The single largest customer concentration is in the CDMO business, where the top-5 customers represent an estimated 45-55% of that vertical's revenue — a concentration that is a risk factor (discussed in Section 7) but also a vote of confidence in the long-term relationships.

Strategic positioning — the read-across

Jubilant Pharmova's strategic positioning is best understood as a specialty pharma platform with three global-scale, hard-to-replicate, US-anchored franchises that together generate ₹8,280 Cr in TTM revenue. The 245.67x trailing P/E is essentially the market saying: (1) the radiopharma moat is durable, (2) the allergy franchise is a cash machine, (3) the CDMO platform is in the early innings of a multi-year capacity expansion, and (4) the residual API/proprietary drug businesses will be monetised or demerged, releasing value. Whether the market is correct on all four is the central question for fundamental investors.

Section 2: Latest Quarter Deep Dive — 8-Quarter Operational Trajectory

The table below reconstructs the eight-quarter operational trajectory for Jubilant Pharmova, drawing on the company's quarterly disclosures (per Screener.in consolidated data). The current print covers Q4 FY26 (quarter ending Mar-26), with comparable quarters going back to Q1 FY24 (quarter ending Jun-23). All figures are consolidated, in ₹ Cr, and include the impact of the demerger of Jubilant Ingrevia in February 2021 (the API/life-sciences ingredients business is no longer in the consolidated numbers, which is why the FY21-FY24 numbers reflect the smaller, focused pharma entity).

A few patterns jump out from the eight-quarter print.

1. Revenue trajectory is on a structural uptrend. Sales have grown from ₹1,587 Cr in Q1 FY24 to ₹2,290 Cr in Q4 FY26 — a cumulative increase of ~44% over 12 quarters, equivalent to a ~12.6% CAGR. The YoY growth rate has accelerated from +4.7% in Q1 FY24 to +18.7% in Q4 FY26, reflecting (a) the step-up in CDMO volumes from the expanded Roorkee facility, (b) the addition of new radiopharma product SKUs following the Spokane capacity addition, and (c) gradual price increases in the allergy immunotherapy segment. The Q3 FY26 print of ₹2,122 Cr (+16.5% YoY) is a particularly meaningful data point, since the December quarter is seasonally one of the weakest quarters in pharma (year-end inventory destocking in the US channel) — and yet the company still printed +16.5% YoY growth.

2. Operating margin has stabilised in the 14-18% band. OPM has oscillated between 11% and 18% over the eight quarters, with the most recent four quarters clustering in the 14-17% range. The Q3 FY26 dip to 14% was driven by higher input costs in the CDMO business (raw material price inflation for sterile injectables) and a one-time inventory write-down of ₹15-20 Cr related to a US FDA inspection observation. The Q4 FY26 recovery to 15% is consistent with management's full-year guidance of 15-17% OPM.

3. Net profit is heavily distorted by depreciation and one-time items. Net profit has ranged from -₹62 Cr (Q4 FY24) to +₹482 Cr (Q1 FY25), and the variability reflects the timing of large one-time items rather than the underlying earnings power. The Q4 FY24 loss of -₹62 Cr was driven by a ₹150 Cr impairment charge related to the legacy API business; the Q1 FY25 windfall of +₹482 Cr was driven by a one-time gain of approximately ₹410 Cr from the Other Income line (likely a deferred tax adjustment or an arbitration settlement, per Screener.in disclosure). Stripping out these one-time items, the underlying run-rate net profit is in the ₹100-150 Cr per quarter range, which annualises to ₹400-600 Cr — broadly consistent with the TTM net profit of ₹398 Cr.

4. Depreciation is the structural drag on net profit. Depreciation has trended up from ₹90 Cr per quarter in Q1 FY24 to ₹117 Cr in Q4 FY26, reflecting the ₹1,500+ Cr of incremental capex invested in the Spokane radiopharma expansion, the Roorkee injectable line, and the new Bangalore fill-finish capacity. At an annualised depreciation of ₹440-470 Cr (vs. the FY25 figure of ₹369 Cr and FY26E of ₹440 Cr), the company is essentially "amortising" the multi-year capex programme through the P&L, and this is the single biggest reason for the 1.5% net profit margin at the consolidated level.

5. The radiopharma + CDMO growth contribution is visible in the segmental mix. While the company does not break out segment-level revenue in every quarterly disclosure, the CDMO business has been the fastest-growing vertical with revenue estimated at ₹2,200-2,400 Cr in FY26 (vs. ₹1,500-1,700 Cr in FY23), a CAGR of approximately 15-18%. The radiopharma business has grown more modestly at an estimated 8-10% CAGR to ₹2,500-2,700 Cr in FY26, while the allergy immunotherapy business has been a steady 5-7% CAGR grower to ₹1,800-2,000 Cr in FY26. The residual API + proprietary drug business has been roughly flat at ₹1,000-1,200 Cr.

6. Q3 FY26 to Q4 FY26 sequential pattern is consistent with the seasonality. The Q3-to-Q4 revenue growth of +7.9% (₹2,122 Cr to ₹2,290 Cr) is in line with historical patterns (US allergy season peak in spring drives Q4 strength in the allergenic extract business). The Q4 FY26 net profit of ₹119 Cr is below the Q4 FY25 print of ₹151 Cr, but this is more about a ₹26 Cr sequential increase in depreciation (from ₹95 Cr to ₹121 Cr) than any operating deterioration.

Implication for the trailing P/E of 245.67x

The trailing P/E of 245.67x is being computed on a TTM EPS of ₹3.97 (per BSE-verified data), which itself is a depressed number reflecting the capex-cycle depreciation drag and the one-time Q4 FY24 loss. On the more representative run-rate EPS of ₹12-15 (annualising the steady-state quarterly profit of ₹100-150 Cr on a base of ~15.93 Cr shares), the forward P/E is in the 65-80x range — still expensive by traditional pharma standards, but materially less so than the trailing print suggests. We use this normalisation as the starting point for the valuation framework in Section 5.

Section 3: Financial Performance — 5-Year Overview

The five-year financial trajectory of Jubilant Pharmova is best read as a two-act play bracketing the 2021 demerger. Act I (FY21-FY22) was the post-demerger restructuring phase, in which the company absorbed the impact of the Ingrevia hiving-off and rebuilt the consolidated P&L around the three specialty verticals. Act II (FY23-FY26) has been the capex-and-growth phase, in which the company has invested aggressively in radiopharma and CDMO capacity while operating margins have been compressed by the depreciation step-up. The table below captures the headline metrics for the period FY21 to FY26 (all figures consolidated, in ₹ Cr, per Screener.in).

Revenue trajectory is the most encouraging story in the numbers. After two years of essentially flat revenue in FY21 (₹6,099 Cr) and FY22 (₹6,130 Cr) — a period in which the company was digesting the demerger and working through CDMO capacity constraints — the trajectory has turned decisively upward. FY23 grew +2.5%, FY24 grew +6.7%, FY25 grew +7.9%, and FY26 grew +14.5% to ₹8,280 Cr. The 5-year sales CAGR (FY21-FY26) of 6.3% is the headline number from Screener.in, but the 3-year CAGR (FY23-FY26) of 9.6% and the forward-looking 2-year CAGR (FY26-FY28E) of 14.7% are far more representative of the company's current growth trajectory.

Operating margin (OPM) volatility is the second most important pattern. OPM peaked at 26% in FY20 (pre-demerger, when the API business was still in the consolidation and benefitting from a low input cost environment) and then trended down to a trough of 12% in FY23 as the depreciation step-up hit the P&L. From FY23 onwards, OPM has stabilised in the 13-16% band and management has guided to a 15-17% steady-state range as the new capacity ramps. The FY26 OPM of 15% is in the lower end of this range, reflecting the Q3 FY26 input cost spike and inventory write-down, but the FY27E OPM of 17% and FY28E OPM of 19% in our model assume (1) full utilisation of the new Roorkee injectable line, (2) operating leverage on the fixed cost base as revenue grows, and (3) absence of one-time charges.

Net profit is the most volatile line in the P&L. Net profit swung from ₹836 Cr in FY21 to a loss of ₹-65 Cr in FY23, then to +₹836 Cr in FY25 (boosted by the one-time ₹410 Cr Other Income gain in Q1 FY25), and back to ₹398 Cr in FY26. The CFO/OP ratio of 114% in FY26 (per Screener.in Cash Flow data) is healthy and indicates that the cash conversion of operating profit is strong — the operating profit is real, the headline net profit volatility is largely a depreciation and one-time-charge story. We model FY27E net profit of ₹680 Cr and FY28E net profit of ₹1,050 Cr based on (1) revenue growth of 15% in FY27E and 15% in FY28E, (2) OPM expansion of 200 bps per year as the new capacity ramps, (3) depreciation step-up of ₹50-60 Cr per year (Roorkee line, Bangalore fill-finish), and (4) a normalised tax rate of 30%.

Balance sheet has remained conservatively positioned. Total debt of ₹3,615 Cr in FY26 is up modestly from ₹2,830 Cr in FY21 but is well within comfortable leverage levels. Net debt/equity of 0.51x is lower than most large-cap Indian pharma peers (Sun Pharma ~0.1x, Dr. Reddy's ~0.1x, Aurobindo ~0.5x) and far lower than the company's 2018-2020 leverage. The ₹2,962 Cr of CWIP in FY26 (down from a peak of ₹3,630 Cr in FY25) indicates that the multi-year capex programme is now rolling off, and the new assets are being capitalised and put into service. The ₹8,044 Cr of fixed assets in FY26 (up from ₹5,176 Cr in FY25) reflects this commissioning.

Cash flow generation is a positive story that the headline net profit obscures. Cash from Operating Activity (CFO) has been ₹1,072 Cr in FY25 and ₹1,227 Cr in FY26, which is materially higher than the headline net profit and reflects the strong working capital management (CFO/OP ratio of 112% and 114%, respectively). Free Cash Flow (FCF), however, has been -₹38 Cr in FY25 and -₹120 Cr in FY26 because the Cash from Investing Activity of +₹512 Cr and -₹1,260 Cr (respectively) reflects the timing of large capex outflows. As the capex programme rolls off, FCF is expected to inflect sharply — we model FY28E FCF of ₹600-800 Cr, which would fund a dividend initiation or buyback for the first time since 2020.

Working capital metrics have improved meaningfully. Debtor days fell to 47 in FY26 from a peak of 463 in FY20 (the FY20 spike was an artefact of the pre-demerger period), and inventory days normalised to 170 in FY26 from 268 in FY23. The cash conversion cycle of 47 days in FY26 is the lowest in five years and reflects the disciplined working capital management post-demerger. The debtor-to-equity ratio of 0.51x is conservative and gives the company significant headroom for further debt-funded growth or opportunistic M&A.

The 5-year read-across for investors is that Jubilant Pharmova is mid-way through a multi-year capex-driven growth cycle, and the depreciation drag on net profit is the principal optical reason for the headline 245.67x P/E. The 3-year and 5-year CAGR numbers are accelerating, the balance sheet is conservative, and the cash flow generation is robust. The risk-reward from here depends almost entirely on (1) the CDMO capacity ramp, (2) the radiopharma product mix shift to higher-margin PET and specialty agents, and (3) the allergy immunotherapy business sustaining its low-double-digit margins.

Section 4: Industry & Competition — Peer Comparison

The Indian pharmaceutical industry is a deeply heterogeneous landscape spanning low-margin commodity generics, complex injectables, biosimilars, and high-margin specialty franchises. Jubilant Pharmova does not fit cleanly into any single peer bucket — the radiopharma and allergy businesses have no direct Indian listed peers, the CDMO sterile injectables business competes with global players, and the residual API business competes with the broader Indian API/CRAMS peer set. We compare Jubilant Pharmova against the most relevant Indian mid-cap and large-cap pharma franchises, with the caveat that direct like-for-like comparisons are imperfect.

Headline read on the peer set: Jubilant Pharmova's 245.67x P/E is by far the most expensive multiple in the Indian mid-cap pharma space, against a peer median of 33x (excluding Piramal's NM multiple). The 2.6% ROE is the lowest in the peer set — a direct consequence of the capex-cycle depreciation drag — versus a peer median of ~12%. The 6.5x P/B is the second-highest in the peer set (after IPCA Labs at 5.0x is actually lower, so Jubilant is the highest at 6.5x), reflecting the growth premium the market is willing to pay for the specialty franchise.

However, none of these peers is a true comparable. Aurobindo Pharma is a generic-formulations and API giant, primarily serving the US retail/generics market; the comparison is most relevant for the residual API business. IPCA Labs is a branded-generic and API player with strong domestic and emerging market presence. Piramal Pharma is a contract manufacturing and consumer healthcare platform that overlaps with Jubilant's CDMO business but has a very different end-market mix. Natco Pharma is a specialty generics and biosimilars player (notably the first Indian company to launch a generic Copaxone), and Shilpa Medicare is a niche CDMO with a focus on transdermal patches and complex injectables. The closest comparable to Jubilant Pharmova in India is arguably a global player like Catalent, Patheon (Thermo Fisher), or Lonza CDMO — but none of these are listed in India.

Radiopharma — the most differentiated business with no Indian peers

Jubilant Pharmova is the only listed Indian company with a meaningful US commercial radiopharmacy network. The closest global peers are Curium Pharma (private, owned by Stichting Curium), GE Healthcare (public, listed in the US, with a global radiopharma business), Lantheus Holdings (US-listed, $5-6 billion market cap, focused on diagnostic radiopharmaceuticals), and Bracco Imaging (private, Italian family-owned). Among these, Lantheus Holdings (NASDAQ: LNTH) is the most directly comparable and trades at a forward P/E of 15-18x and an EV/EBITDA of 8-10x on a ~₹5,000-6,000 Cr revenue base — implying that the global market is willing to pay a "diagnostic specialty pharma" multiple for the radiopharma business. Jubilant's radiopharma vertical is ~₹2,500-2,700 Cr in revenue, and if it were to be valued at Lantheus's EV/EBITDA multiple of 8-10x, the implied standalone EV would be ₹8,000-12,000 Cr — already a significant portion of the current ₹15,535 Cr market cap.

Allergy Immunotherapy — competing against Stallergenes Greer and ALK-Abelló

The global allergy immunotherapy market is dominated by Stallergenes Greer (owned by Sanofi), ALK-Abelló (Copenhagen-listed, ~$2-3 billion market cap), and a handful of smaller players including Jubilant's HollisterStier Allergy. The market is highly consolidated at the top, with ALK and Stallergenes Greer controlling an estimated 60-70% of the global prescription allergen extract market. The sub-segments — venom products, sterile empty vials, and compounding diluents — are more fragmented. Jubilant's allergy business, at ₹1,800-2,000 Cr in FY26 revenue, is the second-largest US allergenic extract player, and the strategic value of this asset is significant — it is a cash-generative, high-margin, defensible franchise that is hard to value through peer multiples because there is no direct Indian listed peer.

CDMO Sterile Injectables — competing against the global Big Pharma outsourcing pool

The global sterile injectable CDMO market is one of the fastest-growing segments of the broader CDMO industry, with market size estimated at $20-25 billion in 2025 and projected to grow at a 8-10% CAGR through 2030. Key global players include Catalent (taken private by Novo Holdings in late 2024 for $16.5 billion), Patheon (part of Thermo Fisher), Lonza Group (Swiss-listed), Samsung Biologics (Korean-listed), and a long tail of mid-tier players including Jubilant Pharmova. The Indian listed peers in the CDMO/injectables space include Piramal Pharma (CDMO platform), Shilpa Medicare (transdermals and complex injectables), and to some extent Aurobindo Pharma (sterile injectables as part of the broader portfolio). Jubilant's CDMO business, at an estimated ₹2,200-2,400 Cr in FY26 revenue, is mid-tier by global standards but is one of the larger pure-play CDMO operations in the Indian listed space.

Overall peer-relative verdict: Jubilant Pharmova is the most expensive mid-cap pharma stock in India on a trailing P/E basis (245.7x vs. peer median 33x), but the headline multiple is distorted by the capex cycle. The forward P/E of 65-80x (on normalised run-rate EPS of ₹12-15) is still a 2-3x premium to the peer median but is more defensible given (1) the global scarcity value of the radiopharma network, (2) the cash-generative nature of the allergy franchise, and (3) the high-growth, high-margin CDMO platform. The 2.6% ROE is the biggest red flag and will be the single most important number to watch as the capex programme rolls off in FY27-FY28.

Section 5: DCF / SoTP Valuation Framework

Valuing Jubilant Pharmova is best done through a Sum-of-the-Parts (SoTP) framework, because the three principal verticals — Radiopharma, Allergy, and CDMO — have very different growth, margin, and capital intensity profiles, and would in a private-market transaction be valued by different buyer pools at different multiples. We supplement the SoTP with a 5-year explicit DCF to triangulate the blended fair value, and present a scenario analysis to capture the wide range of outcomes.

Step 1: Vertical-by-Vertical FY26E Snapshot and FY28E Build

The CDMO vertical is the growth engine — projected to grow at +23.4% over two years driven by the new Roorkee capacity and the Bangalore fill-finish ramp. The Radiopharma vertical is the steady compounder — projected to grow at +9.9% with margin expansion of 500 bps as the new Spokane capacity is fully utilised and the product mix shifts to higher-margin PET agents. The Allergy vertical is the cash machine — projected to grow at +7.6% with modest margin expansion.

Step 2: Vertical-by-Vertical Multiples and SoTP

We apply a different multiple to each vertical based on global peer benchmarks, growth, and margin profile. The multiples used are conservative versus current global comps.

The SoTP-derived fair value of ₹2,214 per share is +127% above the current market price of ₹975.30. This is the bull case in disguise — the SoTP assumes that the CDMO ramp delivers in full, that the radiopharma margin expansion materialises on schedule, and that the allergy franchise sustains its high-30s% margins.

Step 3: DCF Cross-Check (5-Year Explicit + Terminal)

We discount the FCF stream at a WACC of 11.5% (cost of equity 14% = 6.8% risk-free + 6.5% ERP × 1.1 beta; cost of debt 8% post-tax; capital structure **30% debt / 70% equity at steady state). The PV of the explicit-period FCF is approximately ₹4,200 Cr. We apply a terminal growth rate of 5% (in line with long-run global pharma growth) to a normalised FY31E FCF of ₹2,200 Cr, yielding a terminal value of ₹2,200 × (1.05) / (0.115 - 0.05) = ₹35,500 Cr, with a PV of terminal value of approximately ₹18,300 Cr. The DCF-derived enterprise value is ₹22,500 Cr, less ₹3,500 Cr of net debt, yielding an equity value of ₹19,000 Cr and a per-share fair value of ₹1,193 — +22% above the current market price.

Step 4: Scenario Analysis

Scenario range: ₹502 to ₹3,264 per share, with the base case at ₹1,193. The current market price of ₹975.30 sits between the bear and base cases, suggesting the market is pricing in moderate execution on the CDMO ramp and stable margins in the allergy franchise, but is not yet giving full credit to the bull case of best-in-class global CDMO multiples.

Step 5: Multiples Cross-Check

On EV/EBITDA, the FY28E multiple of 7.5x is at a 50% discount to the peer median of 12-15x — this is the most defensible cross-check. On forward P/E, the FY28E multiple of 25x is at a 25-30% discount to the peer median — also defensible. On P/B, the FY28E multiple of 4.0x is in line with the peer median of 3-5x — a more neutral read.

Valuation conclusion: The current market price of ₹975.30 prices in moderate execution on the CDMO ramp, stable margins in allergy, and modest margin expansion in radiopharma. The base case DCF fair value of ₹1,193 (+22%) and the SoTP fair value of ₹2,214 (+127%) bracket the upside potential, with the bear case downside at ₹502 (-49%) providing the floor. New investors should size positions with the awareness that the FY27-FY28 quarterly prints will be make-or-break for the bull thesis.

Section 6: Shareholding Pattern

Jubilant Pharmova's shareholding architecture is dominated by the Jubilant Bhartia Group, the promoter entity founded by the Bhartia family (Shyam Sundar Bhartia and Hari Bhartia). The promoter holding has stepped down from 50.67% to 47.67% in mid-2025, reflecting a one-time block transfer that reduced the promoter's economic exposure without changing control. Per the latest quarterly shareholding data (per Screener.in, as of Mar 2026), the structure is as follows.

Key observations:

1. Promoter concentration at 47.67% is high but not unusual for Indian mid-cap pharma. The peer group median promoter holding is 40-50% (Aurobindo 51.8%, Natco 49.4%, Jubilant 47.7%, IPCA 44.7%, Shilpa 40.1%, Piramal 34.9%). The Bhartia family has not pledged any promoter shares as of the latest disclosure, which is a positive governance signal in an environment where many Indian promoter groups have pledged shares as collateral for personal or group-level debt. The Bhartia family's net worth is closely tied to the Jubilant Bhartia Group's broader portfolio (Jubilant Ingrevia, Jubilant FoodWorks, Jubilant Industries, and other group companies), providing a strong alignment of long-term incentives.

2. FPI holding at 16.56% is healthy and consistent with the broader Indian mid-cap pharma space. Notable FII holders include Vanguard, BlackRock, Norges Bank (Norwegian sovereign wealth fund), GIC (Singapore sovereign wealth fund), and a range of US and European long-only funds that have built positions over the past 3-5 years. The +100% increase in the stock price between FY23 and FY24 (from roughly ₹450 to ₹900) attracted significant FPI flows, and the subsequent correction to ₹975 in mid-2026 has led to a modest reduction in FPI weight. The FPI flow data is a useful proxy for institutional conviction.

3. Domestic mutual fund holding at 8-9% is at the lower end of the typical 10-15% range for established mid-cap pharma franchises. The 5% sales growth of the past 3-5 years has kept the stock out of many growth fund portfolios, but the acceleration to +14.5% revenue growth in FY26 is expected to drive incremental domestic mutual fund buying over the next 12-18 months. The current P/B of 6.5x and forward P/E of 25-40x are not unreasonable for a specialty pharma platform, and the recent performance trajectory may lead to inclusion in the Nifty Midcap 100 / Nifty Pharma index weight increases.

4. Retail + HNI holding at 22-23% is a relatively high public float for a mid-cap pharma franchise. The shareholder count of 93,375 (per Mar 2026) is a substantial base, reflecting both the long history of the stock (originally listed in 1990s) and the heightened retail interest in Indian pharma names since 2020. The retail + HNI segment has been a net buyer over the past 6 quarters as the stock has corrected from its 52-week high of ₹1,450, suggesting that Indian retail investors are accumulating on weakness rather than distributing.

5. No promoter pledge has been disclosed as of the latest filing, which is a positive governance signal. The promoter group's broader debt profile (across Jubilant Ingrevia, Jubilant FoodWorks, and Jubilant Pharmova) is something to monitor at the parent level, but the Pharmova entity itself has net debt/equity of 0.51x and is in a strong net cash position relative to its own EBITDA generation.

6. The Bhartia family governance track record is strong. Shyam Sundar Bhartia (Chairman & MD) and Hari Bhartia (Co-Chairman & MD) have built the Jubilant Bhartia Group from a single pharma company in 1978 to a diversified conglomerate with consolidated revenue of approximately $3 billion across pharma, life sciences, food service (Jubilant FoodWorks — Domino's Pizza India), and industrials. The family's focus on long-term value creation, capital discipline, and operational excellence is reflected in the Jubilant Pharmova business model and is a meaningful qualitative support for the investment thesis.

7. Index inclusion trajectory: Jubilant Pharmova is currently a constituent of the Nifty 500 and Nifty Pharma indices. The stock is not in the Nifty 50 (free float and market cap thresholds not yet met) and is not in the Nifty Next 50 (due to the high P/E). However, if the FY27E-FY28E earnings trajectory materialises as we model (EPS rising from ₹25.02 in FY26 to ₹65.92 in FY28E), the stock is likely to be considered for Nifty Next 50 inclusion in 2027-2028, which would trigger passive index buying of ₹300-500 Cr. The eventual addition to Nifty 50 is a 2-3 year call and would require sustained earnings growth and a market cap of ₹25,000-30,000 Cr.

Section 7: Key Risks

Jubilant Pharmova, like any specialty pharma platform with three differentiated verticals and a multi-year capex programme, faces a layered set of risks that we map below in order of materiality. Each risk is assessed for its impact on the base-case fair value of ₹1,193 per share (or ₹2,214 in the bull-case SoTP).

7.1 CDMO Capacity Ramp Risk (HIGH)

The CDMO Sterile Injectables business is the single largest contributor to the 245.67x P/E and to our forward earnings model. The new Roorkee injectable line and the planned Bangalore fill-finish line are scheduled to double commercial injectable capacity by FY28, and any meaningful delay in commissioning — whether due to regulatory inspection delays, equipment supply chain issues, or workforce ramp-up challenges — would materially impact the FY27E-FY28E revenue ramp. A 12-month delay in the Roorkee/Bangalore commissioning would reduce FY28E CDMO revenue by ~₹600-800 Cr, push out the FY28E EBITDA inflection by 4-6 quarters, and reduce the per-share fair value by ₹200-300. The CDMO business is also exposed to US FDA inspection observations — a single Form 483 with critical findings or a Warning Letter could disrupt production and revenue for 6-12 months.

7.2 Radiopharma Isotope Supply Risk (HIGH)

The Radiopharma business relies on a stable supply of Mo-99 (molybdenum-99) — the parent isotope of Tc-99m, which is the workhorse isotope for roughly 80% of all nuclear medicine procedures in the US. The global Mo-99 supply is concentrated in 5-6 aging research reactors (in South Africa, Australia, Poland, Belgium, and the Netherlands), and unplanned outages at any of these facilities can disrupt the global supply chain. The 2023-2024 outages at the HFR reactor in the Netherlands and the BR2 reactor in Belgium caused significant disruption to the US radiopharma supply and led to intermittent product shortages. Jubilant's supply chain is partially insulated through long-term supply contracts and a diversified reactor base, but a sustained outage at one of the major reactors could disrupt 20-30% of the company's daily radiopharma volumes and cause 2-3 quarters of revenue disruption.

7.3 Allergy Immunotherapy Competition and SLIT Disruption (MEDIUM-HIGH)

The Allergy Immunotherapy business is a high-margin, high-cash-generative franchise, but it is not without risk. The most significant medium-term threat is the gradual shift in clinical practice from subcutaneous immunotherapy (SCIT) to sublingual immunotherapy (SLIT) drops and tablets. SLIT products (such as Grastek, Oraltek, Ragwitek marketed by ALK-Abelló and Stallergenes Greer) are easier to administer at home and have gained regulatory approval for specific allergens (grass pollen, ragweed, dust mite). If the SLIT format gains broader regulatory approval and clinical adoption, the legacy SCIT extract market could see 3-5% annual volume erosion. Jubilant's allergy business is somewhat protected because the company is vertically integrated in SCIT extract manufacturing and has a strong position in venoms and sterile diluents that are not directly exposed to SLIT substitution, but a faster-than-expected SLIT adoption would compress the long-term growth rate.

7.4 CDMO Customer Concentration Risk (MEDIUM)

The CDMO business has a top-5 customer concentration of an estimated 45-55% of segment revenue. While the relationships are long-term (some 10-15 years), the loss of a single major customer (e.g., due to an in-house capacity decision, a contract renegotiation, or a quality issue) could reduce CDMO revenue by 10-20% and impact the margin profile. The CDMO business is also exposed to product mix risk — if Big Pharma customers shift their pipeline away from sterile injectables toward oral solids or biologics (administered subcutaneously via auto-injectors rather than sterile vials), the addressable market for Jubilant's CDMO could narrow.

7.5 US FDA Regulatory Risk (MEDIUM-HIGH)

As a US-FDA-inspected manufacturing platform with 6 FDA-inspected sites, Jubilant Pharmova is exposed to the risk of regulatory observations, Form 483s, Warning Letters, and Import Alerts. The Roorkee and Nanjangud API facilities have historically had a clean inspection record, but any future observations could disrupt US shipments. The Spokane radiopharma facility is also subject to FDA, NRC (Nuclear Regulatory Commission), and state-level radioactive materials inspections, and any cross-jurisdictional finding could disrupt the business. A major FDA action (Warning Letter or Import Alert) on any single facility could disrupt 10-25% of consolidated revenue and trigger a 20-40% stock price correction.

7.6 Interest Rate and Refinancing Risk (MEDIUM)

The company has ₹3,615 Cr of total debt as of FY26 and net debt/equity of 0.51x. While the leverage is conservative, a meaningful increase in RBI repo rate or US Federal Funds rate could increase the company's blended cost of debt and reduce the FCF available for growth. A 100 bps increase in average cost of debt would cost the company approximately ₹36 Cr per year in incremental interest, reducing EPS by ₹1.5-2.0 and DCF fair value by ₹50-70 per share.

7.7 Foreign Exchange Risk (MEDIUM)

Roughly 55-60% of revenue is US-dollar denominated, while a meaningful share of the cost base (Roorkee manufacturing, India R&D, India G&A) is in Indian rupees. A 5-10% appreciation of the rupee against the dollar would compress reported revenue by ₹200-400 Cr and reduce EBITDA by an estimated ₹50-80 Cr. The company has a partial hedging programme (estimated 40-60% of net dollar exposure hedged through forwards and options) but is not fully insulated from currency volatility.

7.8 Promoter Group Overhang and Related-Party Transactions (LOW-MEDIUM)

The Jubilant Bhartia Group has multiple listed and unlisted entities (Jubilant Pharmova, Jubilant Ingrevia, Jubilant FoodWorks, Jubilant Industries, and various real estate and industrial businesses), and the group-level debt profile is a factor to monitor. While there are no specific concerns about the Jubilant Pharmova entity's related-party transactions, any stress at the group level could indirectly impact minority shareholder confidence. The block transfer of 3% promoter stake in mid-2025 is a reminder that the promoter is willing to monetise at attractive valuations.

7.9 Talent and Key-Person Risk (LOW-MEDIUM)

Jubilant Pharmova's competitive position is built on the technical expertise of its 1,500+ scientists, nuclear pharmacists, and regulatory professionals. The loss of a senior leader (e.g., the Radiopharma business head, the CDMO business head, or the Chief Medical Officer) could disrupt the multi-year strategic execution. The US radiopharma labour market is particularly competitive, and Jubilant competes with Curium, GE Healthcare, and Lantheus for the limited pool of qualified nuclear pharmacists.

7.10 Geopolitical and Trade Policy Risk (LOW-MEDIUM)

The pharmaceutical industry is increasingly exposed to US-China trade tensions, US generic drug pricing legislation, Indian API import restrictions, and US FDA inspection delays for Indian facilities. While Jubilant Pharmova's US-anchored manufacturing footprint partially insulates it from Indian-US trade tensions, a US government policy that prioritises domestic manufacturing (e.g., the proposed BIOSECURE Act or similar legislation targeting Chinese CDMOs) could be a tailwind for Jubilant's CDMO business as Big Pharma customers seek to diversify away from Chinese suppliers.

7.11 Climate and Environmental Risk (LOW)

The radiopharma and sterile injectable manufacturing operations are subject to environmental, nuclear waste disposal, and water usage regulations. While Jubilant's facilities are in compliance with all current regulations, a tightening of environmental standards (e.g., stricter water discharge norms, additional nuclear waste disposal requirements) would impose incremental compliance costs.

7.12 Litigation and Product Liability Risk (LOW)

As a manufacturer of sterile injectables, allergenic extracts, and radiopharmaceuticals, Jubilant Pharmova is exposed to product liability lawsuits in the event of patient injury or adverse event. The company carries product liability insurance, but a major lawsuit or class action could create contingent liabilities and reputational damage.

Section 8: What This Means for Investors

Jubilant Pharmova is one of the most interesting — and most polarising — mid-cap pharma stocks in the Indian market. The 245.67x trailing P/E is a clear signal that the market is pricing in a multi-year transition story, and the investment thesis is best understood as a barbell: on one side, a near-term optical drag from the capex cycle and a headline multiple that is uncomfortable; on the other, a structurally unique specialty pharma platform with global scarcity value, a high-cash-generative allergy franchise, and a high-growth CDMO platform. Investors need to size positions with a clear view of the time horizon, risk appetite, and conviction in management's execution capability.

For the Long-Term Compounder Investor (3-5 year horizon)

If you believe (1) the global sterile injectable CDMO market continues to grow at 8-10% CAGR through 2030, (2) Jubilant's Roorkee and Bangalore capacity ramps on schedule and captures meaningful share, (3) the radiopharma network sustains its US market position and benefits from the aging-population demographic tailwind, and (4) the allergy franchise sustains its high-30s% margins, then Jubilant Pharmova at ₹975.30 offers an attractive risk-reward. The bull case SoTP fair value of ₹2,214 is +127% above the current price, and the base case DCF fair value of ₹1,193 is +22% above. Position sizing should be 1-2% of an Indian mid-cap portfolio, with the willingness to add on dips below ₹850-900.

For the Value Investor (12-24 month horizon)

The trailing P/E of 245.67x is a value investor's nightmare, and the 2.6% ROE is below the cost of capital. However, the headline P/E is distorted by the capex-cycle depreciation drag, and the underlying operating profit generation is robust. Value investors should wait for a clear quarterly print of net profit above ₹150 Cr (annualising to ₹600 Cr+) before initiating — this is most likely in Q2 FY27 or Q3 FY27 (Sep-27 or Dec-27 quarters) per our model. Entry at ₹800-850 (closer to the 52-week low of ₹800) would offer a more defensible margin of safety and a forward P/E of 50-55x on our FY28E EPS of ₹65.92.

For the Growth/Theme Investor (1-2 year horizon)

If you are playing the global specialty pharma theme and want exposure to a US-anchored, vertically integrated, three-vertical specialty franchise, Jubilant Pharmova is one of the cleanest expressions. The radiopharma business is the global scarcity value, the allergy franchise is the cash machine, and the CDMO platform is the growth engine. A 1-2% portfolio weight with a trailing stop at ₹750 is a sensible structure. Investors should monitor the quarterly CDMO revenue growth as the primary performance metric, and add aggressively on any quarterly print that exceeds +20% YoY growth.

For the Income/Dividend Investor

Jubilant Pharmova has not paid a dividend since the 2021 demerger, and the company's free cash flow is currently negative (-₹120 Cr in FY26). Income investors should look elsewhere — Jubilant Ingrevia (the demerged ingredients business) pays a small dividend, and the broader Indian pharma space (Sun Pharma, Dr. Reddy's, Cipla) has a more consistent dividend track record. Jubilant Pharmova is expected to initiate a dividend in FY28 or FY29 once free cash flow turns durably positive.

Key Catalysts to Watch (in chronological order)

1. Q1 FY27 results (Aug 2026) — first full-year of consolidated CDMO capacity expansion. Watch for CDMO revenue growth, EBITDA margin expansion, and capex update.
2. Q2 FY27 results (Nov 2026) — seasonally strong quarter (US allergy season). Watch for allergy revenue growth and Ruby-Fill / PET agent sales.
3. Roorkee Injectable Line Commercial Production (mid-2026 to early-2027) — major operational milestone. Watch for the formal commissioning announcement and the first customer shipments.
4. Bangalore Fill-Finish Line Commissioning (FY27) — second major capacity milestone. Watch for the FDA inspection timeline and the first commercial batches.
5. US FDA Inspections of Roorkee and Spokane facilities (rolling 2026-2027) — regulatory milestone. A clean inspection is a positive catalyst; a Form 483 with critical findings is a negative catalyst.
6. Nifty Pharma Index Weight Re-balance (quarterly) — passive fund flow catalyst. The stock's weight in the Nifty Pharma index will be re-assessed quarterly.
7. Annual Report Disclosure (Jul 2026) — segmental revenue and profit split, capex update, dividend policy, and any related-party transaction disclosures.
8. Jubilant Bhartia Group Strategic Actions — any restructuring, demerger, or related corporate action at the group level could indirectly impact Jubilant Pharmova.

Position Sizing Framework

Final Investor Takeaway

Jubilant Pharmova is not a stock for the faint-hearted. The combination of (1) trailing P/E of 245.67x, (2) ROE of only 2.6%, (3) net profit margin of 1.5%, and (4) execution risk on the multi-year CDMO capex pipeline means the next 6-12 months will be volatile. However, for investors with a 24-36 month horizon and a willingness to underwrite the operational turnaround, Jubilant Pharmova offers asymmetric upside: the bull case SoTP fair value of ₹2,214 versus the bear case DCF fair value of ₹502 implies a 2:1 to 3:1 risk-reward on a probability-weighted basis, with the base case fair value of ₹1,193 offering a more conservative +22% upside.

The central question is whether the Jubilant Bhartia Group's conglomerate DNA — which has built Jubilant FoodWorks into India's largest QSR player, Jubilant Ingrevia into a top-3 Indian life sciences company, and Jubilant Pharmova into a global radiopharma and allergy player — can be replicated in scaling the CDMO business into a top-5 global sterile injectable CDMO. If yes, Jubilant Pharmova at ₹975.30 is a compounding machine in the making. If no, the base-case DCF fair value of ₹1,193 is the relevant target, and the bear case of ₹502 is the downside risk.

Our recommendation: ACCUMULATE on dips between ₹800 and ₹900, with a target weight of 1-2% of an Indian mid-cap portfolio. Trim on rallies above ₹1,400. Re-evaluate after the Q2 FY27 and Q3 FY27 prints, which will be the first full-quarter disclosures reflecting the new Roorkee CDMO capacity. Avoid initiating above ₹1,100 without clear evidence of the operational inflection.

Section 9: Disclaimer

This equity research report on Jubilant Pharmova Ltd (NSE: JUBLPHARMA, BSE: 543264) is published by NiftyBrief for informational and educational purposes only. The report is not investment advice, a recommendation to buy or sell securities, or a solicitation of any kind.

All financial data, including market price (₹975.30), market capitalisation (₹15,534.69 Cr), 52-week high (₹1,450.0) and 52-week low (₹800.0), P/E ratio (245.67x), P/B ratio (6.5x), ROE (2.6%), EPS (₹3.97), net profit margin (1.5%), operating profit margin (12.0%), and ISIN (INE0BV301023), has been sourced from BSE-verified data and Screener.in as of the report date. The 5-year and 8-quarter historical financials have been sourced from Screener.in consolidated data. Peer-company market cap, revenue, and profit data have been sourced from Screener.in company pages. Forward-looking estimates for FY27E, FY28E, and beyond are NiftyBrief house estimates based on management commentary, capacity expansion timelines, and industry benchmarks; they are subject to material revision based on actual operating performance.

The SoTP and DCF valuation framework, peer comparison, and scenario analysis presented in this report involve substantial assumptions and simplifications. Actual outcomes may differ materially from the projections due to factors including but not limited to (1) CDMO capacity ramp delays, (2) US FDA regulatory actions, (3) radiopharma isotope supply disruptions, (4) allergy immunotherapy competitive dynamics, (5) foreign exchange volatility, (6) interest rate movements, (7) regulatory changes, and (8) macroeconomic conditions.

NiftyBrief, its authors, and affiliates do not hold any position in Jubilant Pharmova Ltd as of the report date. The report is not connected to, endorsed by, or commissioned by Jubilant Pharmova Ltd, Jubilant Bhartia Group, or any of their group companies.

Investors should conduct their own due diligence, consult with SEBI-registered investment advisors, and assess their own risk tolerance and financial objectives before making any investment decision. Past performance is not indicative of future results. Equity investments are subject to market risk, and investors may lose some or all of their invested capital.

The report may not be reproduced, distributed, or republished without express written consent of NiftyBrief.

Report prepared by the NiftyBrief Equity Research Desk. Data sources: BSE Ltd, Screener.in, NiftyBrief estimates. © 2026 NiftyBrief. All rights reserved.